3 research outputs found
Additional file 3: Table S1. of Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways
All ovarian cancer cell lines and their culture conditions. (XLSX 13 kb
Additional file 1: Figure S1. of Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways
a Clinicopathological features of transplanted HGSOC tumors. b Representation of patients and their corresponding PDX tumor samples used in this study. c All preprocessing of 450 K data of each sample. d DNA methylation level of each sample type according to HIL CpG classes [38] for PDX-36, -37, and -56 for all generation tumors (F0, F1, F2, and F3), p < 0.01. e Global distribution of 450 K methylation probes of the raw data of PDX-36, -37, and -56 for all generation tumors (F0, F1, F2, and F3). f Validation of global methylation using bisulfite pyrosequencing of ALU-Yb8 in PDX samples. Each bar represents average methylation (%) ± SD of five CpG sites for ALU-Yb8 in the indicated PDX samples. g Correlation heat map of PDX-36 biological replicates (n = 3) of generation F3 based on their genome-wide CpGs β values. Pearson correlation coefficients are shown in each heatmap box. (PDF 620 kb
Antibody-Free LC-MS/MS Quantification of rhTRAIL in Human and Mouse Serum
The major challenge in targeted protein
quantification by LC-MS/MS
in serum lies in the complexity of the biological matrix with regard
to the wide diversity of proteins and their extremely large dynamic
concentration range. In this study, an LC-MS/MS method was developed
for the simultaneous quantification of the 60-kDa biopharmaceutical
proteins recombinant human tumor necrosis factor-related apoptosis-inducing
ligand wild type (rhTRAIL<sup>WT</sup>) and its death receptor 4 (DR4)-specific
variant rhTRAIL<sup>4C7</sup> in human and mouse serum. Selective
enrichment of TRAIL was accomplished by immobilized metal affinity
chromatography (IMAC), which was followed by tryptic digestion of
the enriched sample and quantification of a suitable signature peptide.
For absolute quantification, <sup>15</sup>N-metabolically labeled
internal standards of rhTRAIL<sup>WT</sup> and rhTRAIL<sup>4C7</sup> were used. Since the signature peptides that provided the highest
sensitivity and allowed discrimination between rhTRAIL<sup>WT</sup> and rhTRAIL<sup>4C7</sup> contained methionine residues, we oxidized
these quantitatively to their sulfoxides by the addition of 0.25%
(w/w) hydrogen peroxide. The final method has a lower limit of quantification
of 20 ng/mL (ca. 350 pM) and was fully validated according to current
international guidelines for bioanalysis. To show the applicability
of the LC-MS/MS method for pharmacokinetic studies, we quantified
rhTRAIL<sup>WT</sup> and rhTRAIL<sup>4C7</sup> simultaneously in serum
from mice injected intraperitoneally at a dose of 5 mg/kg for each
protein. This is the first time that two variants of rhTRAIL differing
by only a few amino acids have been analyzed simultaneously in serum,
an approach that is not possible by conventional enzyme-linked immuno-sorbent
assay (ELISA) analysis